Hester Biosciences’ shares soared by 11.21% today, reaching ₹2,474.65, following the announcement of robust Q2 FY25 results. The company’s strong financial performance has sparked investor confidence, driving the stock price upward.
Q2 FY25 Key Highlights:
- Revenue from Operations increased by 18.8% year-on-year (YoY), rising to ₹83.69 crores from ₹70.45 crores in Q2 FY24.
- Profit After Tax (PAT) surged by 107.4% YoY, reaching ₹8.39 crores compared to ₹4.04 crores in the corresponding quarter of the previous fiscal.
EBITDA Growth and Margins:
- EBITDA for Q2 FY25 reached ₹19.2 crores, reflecting a 45.4% YoY growth compared to ₹13.2 crores in Q2 FY24.
- EBITDA Margin improved significantly, standing at 22.94% in Q2 FY25, compared to 18.72% in Q2 FY24.
The market has responded positively to these impressive figures, leading to a notable 11% increase in the company’s share price. Investors are optimistic about the company’s future growth trajectory following its strong quarterly performance.
